Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
Lin KH, Hsu PI, Yu HC, Lin CK, Tsai WL, Chen WC, Chan HH, Lai KH.
BMC Gastroenterol. 2012 Jan 18;12:7.
Related citations
HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.
Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ.
Gastroenterology. 2012 Apr;142(4):978-88. Epub 2012 Jan 13.
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B, Lu XY, Ipe D, Lopatin U, Germer S, Iglesias VA, Elston R, Smith PF, Shulman NS.
Gastroenterology. 2012 Apr;142(4):790-5. Epub 2012 Jan 13.
The role of the gut barrier function in the pathophysiology of viral liver cirrhosis.
Choi Y, Jeon WK, Hwang SJ, Kim BI, Sohn CI, Park DI, Cho YK, Kim HJ, Park JH.
Hepatogastroenterology. 2011 Jul-Aug;58(109):1244-7. doi: 10.5754/hge10338.
Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen.
Murakami K, Takahashi R, Ono M, Watanabe K, Okimoto T, Kodama M, Abe D, Kimura M, Fujioka T.
J Gastroenterol. 2011 Sep;46(9):1120-6. Epub 2011 Jun 8.
Understanding silibinin's modes of action against HCV using viral kinetic modeling.
Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS.
J Hepatol. 2012 May;56(5):1019-24. Epub 2012 Jan 13.
Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.
J Med Virol. 2012 Mar;84(3):438-44. doi: 10.1002/jmv.23207.
Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
Chary A, Winters MA, Eisen R, Knight TH, Asmuth DM, Holodniy M.
J Med Virol. 2012 Mar;84(3):431-7. doi: 10.1002/jmv.23210.
New developments in HCV therapy.
Kronenberger B, Zeuzem S.
J Viral Hepat. 2012 Jan;19 Suppl 1:48-51. doi: 10.1111/j.1365-2893.2011.01526.x.
Steatosis and insulin resistance in response to treatment of chronic hepatitis C.
Negro F.
J Viral Hepat. 2012 Jan;19 Suppl 1:42-7. doi: 10.1111/j.1365-2893.2011.01523.x. Review.
Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.
Rumi M, Aghemo A, Prati GM.
J Viral Hepat. 2012 Jan;19 Suppl 1:37-41. doi: 10.1111/j.1365-2893.2011.01525.x. Review.
How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?
Sebastiani G, Alberti A.
J Viral Hepat. 2012 Jan;19 Suppl 1:18-32. doi: 10.1111/j.1365-2893.2011.01518.x.
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Simón-Talero M, Buti M, Esteban R.
J Viral Hepat. 2012 Jan;19 Suppl 1:14-7. doi: 10.1111/j.1365-2893.2011.01521.x.
Optimal treatment duration for patients with HCV genotype 1 infection.
Ferenci P.
J Viral Hepat. 2012 Jan;19 Suppl 1:7-13. doi: 10.1111/j.1365-2893.2011.01522.x.
Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C.
Degasperi E, Aghemo A.
J Viral Hepat. 2012 Jan;19 Suppl 1:3-6. doi: 10.1111/j.1365-2893.2011.01517.x.
Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.
Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O.
J Viral Hepat. 2012 Feb;19(2):e97-104. doi: 10.1111/j.1365-2893.2011.01512.x. Epub 2011 Oct 4.
Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation.
Grover VP, Pavese N, Koh SB, Wylezinska M, Saxby BK, Gerhard A, Forton DM, Brooks DJ, Thomas HC, Taylor-Robinson SD.
J Viral Hepat. 2012 Feb;19(2):e89-96. doi: 10.1111/j.1365-2893.2011.01510.x. Epub 2011 Oct 17.
Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R.
J Viral Hepat. 2012 Feb;19(2):e81-8. doi: 10.1111/j.1365-2893.2011.01507.x. Epub 2011 Aug 16.
Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication.
Rance E, Tanner JE, Alfieri C.
J Viral Hepat. 2012 Feb;19(2):e73-80. doi: 10.1111/j.1365-2893.2011.01505.x. Epub 2011 Aug 16.
Ischaemic colitis during interferon treatment for chronic hepatitis C: report of two cases and literature review.
Kawaguchi T, Ide T, Itou M, Suetsugu M, Yoshioka S, Sakata M, Taniguchi E, Oriishi T, Sumie S, Tsuruta O, Sata M.
J Viral Hepat. 2012 Feb;19(2):e220-4. doi: 10.1111/j.1365-2893.2011.01501.x. Epub 2011 Aug 4. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on